Literature DB >> 9207949

Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa.

M J Fisher1, B Gunn, C S Harms, A D Kline, J T Mullaney, A Nunes, R M Scarborough, A E Arfsten, M A Skelton, S L Um, B G Utterback, J A Jakubowski.   

Abstract

Cyclic heptapeptide 1, which contains an Arg-Gly-Asp sequence, has good affinity for the platelet receptor GPIIb-IIIa and was chosen for study by 1H NMR techniques. The key RGD sequence of this molecule was found to reside in a conformationally defined type II' Gly-Asp beta-turn, and this information was used in the design of simple non-peptide RGD mimics. Disubstituted isoquinolones, bearing an acidic side chain at position 2 and a basic side chain at position 6, were prepared and were found to have modest affinity for GPIIb-IIIa. Systematic modification of the basic residue contained in these molecules yielded compounds with high affinity for GPIIb-IIIa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207949     DOI: 10.1021/jm9701076

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  [Therapy of acute coronary syndrome. Aspirin, heparin, low-molecular-weight heparin, hirudin and GP-IIb/IIIa blockers].

Authors:  A Gaede; W Terres
Journal:  Herz       Date:  1999-08       Impact factor: 1.443

2.  Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.

Authors:  Seetharama Satyanarayanajois; Stephanie Villalba; Liu Jianchao; Go Mei Lin
Journal:  Chem Biol Drug Des       Date:  2009-09       Impact factor: 2.817

3.  Secondary structure, a missing component of sequence-based minimotif definitions.

Authors:  David P Sargeant; Michael R Gryk; Mark W Maciejewski; Vishal Thapar; Vamsi Kundeti; Sanguthevar Rajasekaran; Pedro Romero; Keith Dunker; Shun-Cheng Li; Tomonori Kaneko; Martin R Schiller
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

4.  Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy.

Authors:  Li Liu; Xiaoxia Liu; Qian Xu; Ping Wu; Xialin Zuo; Jingjing Zhang; Houliang Deng; Zhuomin Wu; Aimin Ji
Journal:  Int J Nanomedicine       Date:  2014-07-29

5.  Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.

Authors:  Zhongya Chen; Jiaxin Deng; Yan Zhao; Tao Tao
Journal:  Int J Nanomedicine       Date:  2012-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.